Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Selectins

Selectins

Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.

Human gene therapy·2025

Same author

Unraveling the power of NAP-CNB's machine learning-enhanced tumor neoantigen prediction.

eLife·2025

Same author

Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis.

Molecular therapy. Oncology·2025

Same author

Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy.

Molecular therapy. Oncology·2024

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Cancer selective adenoviruses.

Ramon Alemany¹

¹Virus Therapy Group, Translational Research Laboratory, Institut Català d'Oncologia, Barcelona, Spain. ralemany@iconocologia.net

Molecular Aspects of Medicine

|February 16, 2007

Summary

Oncolytic adenoviruses show promise but require improved tumor selectivity and delivery. Future strategies involve arming viruses with transgenes to enhance efficacy and overcome biological barriers for better cancer treatment.

Area of Science:

Oncolytic virotherapy
Adenovirus research
Cancer gene therapy

Background:

The initial oncolytic adenovirus, dl1520 (Onyx-015), inspired further development but had limitations.
Despite early promise, challenges in selectivity and tumor targeting persist for oncolytic adenoviruses.

Purpose of the Study:

To review the progress and persistent challenges in the clinical development of oncolytic adenoviruses.
To explore strategies for enhancing the efficacy of oncolytic adenoviruses through improved targeting and transgene applications.

Main Methods:

Review of preclinical models and clinical biodistribution data for oncolytic adenoviruses.
Analysis of strategies for overcoming tumor microenvironment barriers and enhancing viral spread.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Related Experiment Videos

Last Updated: Jul 17, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Main Results:

Limited tumor accumulation of systemically administered oncolytic adenoviruses is a significant hurdle.
Tumor stroma and immune responses impede efficient viral spread within the tumor.
Transgene incorporation offers a dual approach to boost virus replication and directly eliminate tumor cells.

Conclusions:

Further advancements in selectivity, retargeting, and pharmacokinetic profiling are crucial for oncolytic adenoviruses.
Arming oncolytic viruses with transgenes presents a viable strategy to enhance tumor cell killing and viral propagation.
Careful clinical development, incorporating collaborative efforts and intellectual property, is essential for successful translation of next-generation oncolytic adenoviruses.